Foghorn Therapeutics (FHTX) Capital Leases (2021)
Foghorn Therapeutics (FHTX) posted quarterly Capital Leases of $198000.0 for Q2 2021, down 12.0% quarter-over-quarter from $225000.0 in Q1 2021.
Powered by 
Analysis
Foghorn Therapeutics (FHTX) Capital Leases (2021) Analysis & Trends
Foghorn Therapeutics' Capital Leases history runs 1 years deep, the most recent figure standing at $198000.0 for Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Foghorn Therapeutics | 347.14 Mn | 279.06 Mn | - |